HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Evolution of psycho-oncology reflects ‘emotional, spiritual and social level’ of cancer care
-
- ASH to present mentorship awards
- BRAF/MEK inhibitor combination extends PFS in melanoma
- Chemists develop low-cost, at-home test to detect cancer, malaria
- Dana-Farber Cancer Institute professor to join Eli Lilly as senior VP for oncology
- Fostamatinib superior to placebo in chronic ITP
- Huntsman Cancer institute appoints executive director
- Immunotherapy expert joins Rush University Medical Center
- Mortality burden gap narrows between heart disease, cancer in US
-
- Pacritinib improves response rate, fails to reduce symptom score in high-risk myelofibrosis
- Physicians join Roswell Park Cancer Institute community practice
- Roswell Park Cancer Institute names senior vice president of nursing
- Survey: Americans consider cancer nation's top health care challenge
- Vanderbilt lung cancer researcher receives LUNGevity award
- Cancer screening: The stars are aligned John Sweetenham, MD, FRCP, FACP
- FDA approves companion diagnostic test for Tagrisso in NSCLC
- FDA grants breakthrough designation to NiCord for bone marrow transplantation
-
- FDA grants breakthrough therapy designation to Alecensa for first-line treatment of ALK–positive NSCLC
- FDA grants fast track designation to galinpepimut-S for malignant plural mesothelioma
- FDA warns against combining opioids and benzodiazepines
- Keytruda receives FDA breakthrough therapy designation, priority review for first-line NSCLC
- Adaptive image-guided radiation therapy may improve bladder preservation
- Ado-trastuzumab emtansine effective for previously treated HER-2–positive metastatic breast cancer
- Bevacizumab may prolong PFS after progression of advanced NSCLC
- Daratumumab-based triplet highly effective in relapsed, refractory myeloma
-
- Dasatinib, low-intensity chemotherapy effective for older patients with ALL
- Dexrazoxane may reduce, prevent cardiotoxicity in childhood cancer survivors
- Edoxaban safe, effective for extended prevention of recurrent VTE
- Long-term exposure to particulate matter increases cancer mortality
- Low vitamin D increases risk for adverse pathology of localized prostate cancer
- Lower vitamin D levels associated with worse outcomes in melanoma
- Most parents support school-entry HPV vaccination requirements if opt-outs exist
- Novel surgical approach improves local recurrence rates in oral cancers
-
- Olanzapine prevents nausea in patients treated with emetogenic chemotherapy
- Open, robotic prostatectomy produce similar early functional outcomes
- Oral contraception use leads to worldwide decline in ovarian cancer mortality
- PSA testing cost-effective when used conservatively
- Rare genetic variant may predict Barrett esophagus, esophageal cancer
- Rituximab maintenance for indolent lymphoma prolongs PFS, not OS
- Skeletal muscle mass, BMI predict survival in radiotherapy-treated HNSCC
- Wider surgical margins needed for thicker primary cutaneous melanoma
-
- Cabozantinib extends PFS in metastatic renal cell carcinoma
- Financial toxicity associated with poorer quality of life, survival outcomes
- IMRT reduces toxicity, improves quality of life in women with cervical, endometrial cancers
- Niraparib prolongs PFS in recurrent ovarian cancer
- Novel agent crosses blood-brain barrier to treat CNS metastases from breast cancer
- Olaparib fails to extend OS in advanced gastric cancer
- Pembrolizumab extends survival in advanced, PD-L1–positive NSCLC
- Postoperative stereotactic radiosurgery improves local control of brain metastases
-
- Researchers identify three novel intrinsic subtypes of prostate cancer
- Ribociclib plus letrozole extends PFS in hormone receptor–positive, HER-2–negative advanced breast cancer
- Should all patients with cancer receive mental health counseling?